Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$2.51M$2.51M+15.2% vs Q2 2018 Net Income-$8.90M-$8.90MN/M vs Q2 2018 EPS Diluted-$0.29-$0.29N/M vs Q2 2018 Operating Income-$8,942,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,206,000N/M Margins · derivedOperating margin-355.7%+50.4 pt vs Q2 2018
Net margin-353.9%+45.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end